(VIANEWS) – Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) fell by a staggering 20.8% in 14 days from $15.53 to $12.30 at 10:58 EST on Monday, after five sequential sessions in a row of losses. NASDAQ is jumping 1.03% to $10,979.98, after four sequential sessions in a row of losses.

Catalyst Pharmaceuticals’s last close was $11.87, 31.07% under its 52-week high of $17.22.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm at the commercial stage. It focuses its efforts on commercializing treatments for neurological and rare neuromuscular diseases. Firdapse is an amifampridine-phosphate tablet for patients suffering from lambert–eaton syndrome (LEMS). Ruzurgi can be used to treat LEMS children. Firdapse is also developed by the company to treat MuSK antibody positive myasthenia Gravis and spinal muscular atrophy Type 3. It can also be used to treat hereditary nervepathy with liability for pressure palsies. Endo Ventures Limited and BioMarin Pharmaceutical Inc. have license agreements. Endo Ventures Limited has a collaboration agreement for the commercialization and development of generic Sabril tablets. Catalyst Pharmaceutical Partners, Inc. was the company’s former name. It changed its name in May 2015 to Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc., was established in 2002. It is located in Coral Gables, Florida.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of 0.71.

PE Ratio

Catalyst Pharmaceuticals has a trailing 12 months price to earnings ratio of 17.32. Meaning,
the purchaser of the share is investing $17.32 for every dollar of annual earnings.

Return on Equity (TTM)

Catalyst Pharmaceuticals’s ROE is 22.59.


Today’s last reported volume for Catalyst Pharmaceuticals is 455521 which is 86% below its average volume of 3255552.

Catalyst Pharmaceuticals’s Sales

Catalyst Pharmaceuticals’s sales growth is 55% for the present quarter and 43.7% for the next. The company’s growth estimates for the current quarter and the next is 90% and 111.1%, respectively.

Catalyst Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 42.7%, now sitting on 153.72M for the twelve trailing months.


Catalyst Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.24%, a negative 0.15%, and a positive 3.08%, respectively.

Catalyst Pharmaceuticals’s highest amplitude of average volatility was 4.74% (last week), 3.07% (last month), and 3.08% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Catalyst Pharmaceuticals’s stock is considered to be overbought (>=80).

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $12.30 at 10:58 EST, way under its 52-week high of $17.22 and way higher than its 52-week low of $5.00.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is below its 50-day moving average of $12.53 and way higher than its 200-day moving average of $8.53.

More news about Catalyst Pharmaceuticals (CPRX).


Please enter your comment!
Please enter your name here